Clinical Trials Logo

Clinical Trial Summary

The purpose of this prospective study is to compare the clinical and radiographic success of MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary molars in a pediatric population. There is limited research currently on Biodentine since it's a novel product. Biodentine is less expensive than MTA and does not cause discoloration like MTA. Biodentine may be an alternative medicament used for vital pulp therapy in primary molars.

Clinical Trial Description

This is a interventional randomized split mouth prospective study that evaluates the clinical and radiographic success of mineral trioxide aggregate (MTA) and Biodentine as pulpotomy and indirect pulp cap (IPC) medicaments. Male and female participants ages two to twelve who need at least two quadrants of treatment will be enrolled in the trial. Participants will be treated at Geisinger Medical Center, Danville, and Geisinger Bloomsburg Hospital operating rooms for full mouth rehabilitation. Each participant must have at least two matched bilateral carious primary molars that require either pulpotomy or indirect pulp cap. Maxillary and mandibular primary first and second molars who receive pulpotomy and /or indirect pulp cap will be compared. The research will be split mouth design where the primary molar on one side will get MTA as the pulpotomy or IPC medicament and the corresponding primary on the other side will get Biodentine as the pulpotomy or IPC medicament in the same arch. The procedures will be performed according to standards of the American Academy of Pediatric Dentistry (AAPD), by IRB approved investigators. Data will be extracted from the electronic health record (EHR) and TigerView dental radiograph imaging software. Data will be recorded using REDCap. Clinical and radiographic follow up of patients will be every 6 months since date of procedure for 3 years. Follow up will be done at the Geisinger Pediatric Dental Clinic at Danville or Milton. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04863222
Study type Interventional
Source Geisinger Clinic
Contact Gayatri Malik, DMD
Phone 570-271-6355
Email [email protected]
Status Not yet recruiting
Phase Phase 4
Start date June 2021
Completion date July 1, 2024

See also
  Status Clinical Trial Phase
Withdrawn NCT01878851 - Characterization of Blood Drawn From the Pulp of Primary Molar Undergoing Pulpotomy or Pulpectomy.
Completed NCT04270318 - Sodium Hypoclorite as an Antibacterial Agent Prior to Pulpotomies N/A
Completed NCT03200938 - Clinical Applicability of PBS® CIMMO Cement in Pulpotomies N/A
Completed NCT03779698 - BiodentineTM Versus Formocresol Pulpotomy Technique in Primary Molars Phase 4
Completed NCT03395496 - Comparison of Biodentine and MTA Pulpotomies in the Primary Molar Teeth 3 Year Follow up Early Phase 1
Completed NCT03718676 - Pulpotomy With Various MTA Materials and Ferric Sulphate N/A
Recruiting NCT02298504 - Vital Pulp Treatment in Primary Teeth Phase 4
Completed NCT04010929 - Efficacy of Er,Cr:YSGG Laser in Partial Pupotomy N/A
Withdrawn NCT02393326 - Biodentine Partial Pulpotomy of Pulpally Exposed Primary Molars N/A
Completed NCT03782714 - Low-level Laser Therapy Versus Formocresol in Primary Molar Pulpotomies N/A
Terminated NCT03786302 - Regenerative Ability of TAMP BG and BD in Pulpotomized Primary Teeth Phase 2
Active, not recruiting NCT03522051 - Assessment of Pulpotomy Procedure Using NeoMTA Plus in Permanent Teeth With Carious Exposure N/A
Terminated NCT02783911 - Comparison of Mineral Trioxide Aggregate (MTA) & Ferric Sulfate (FS) Pulpotomies N/A